SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2669)9/29/2001 10:22:46 PM
From: TomatoRead Replies (1) | Respond to of 4974
 
"there's probably not much to stop Glass from letting the cash ride where it may. More power to Glass/Icahn if they pick something good outside of biotech. I still think that the potential royalty flow would add tons of "sexy" to a prospectus. Find some great functional genomics company and merge them with KDUS instead of doing a mezzanine?"

But....didn't someone at the KDUS annual meeting say that Glass seemed generally unaware of the potential royalty flow? That seemed rather perturbing at the time. Wonder if he's been wised up?



To: scaram(o)uche who wrote (2669)9/30/2001 8:21:08 AM
From: nigel batesRead Replies (1) | Respond to of 4974
 
I'm not certain that funding will be that tight. The sector is very, very strong

Of course. The conventional wisdom is usually wrong.
I can't see to many IPOs happening, though. Reverse takeovers of cash shells like KDUS would make a lot of sense for those who really want to get a listing.

A group of SI biofreaks participated in a round that closed last week. Great opportunity.

Not a "great functional genomics company" by any chance ? <g>

nig


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News